Blood Cancer UK: Hopes for our community’s future in the time of COVIDThis thought leadership series has been paid and developed by Kite, a Gilead Company. This Blood Cancer Awareness Share XBlood Cancer UK: Hopes for our community’s future in the time of COVIDhttps://pharmaphorum.com/oncology/blood-cancer-uk-hopes-for-our-communitys-future-in-the-time-of-covid/
How pharma can help the post-COVID recovery of European cancer careThe new Cancer Care in Europe: Recovering from COVID-19 Disruption white paper assesses the disruption to patient care and Share XHow pharma can help the post-COVID recovery of European cancer carehttps://pharmaphorum.com/whitepapers/pharma-covid-recovery-cancer-care/
Collaborate to simplify cancer trials and accelerate post-pandemic recoveryHow could simplifying the administration of clinical trials help cancer diagnosis, care, and treatment levels to exceed pre-pandemic Share XCollaborate to simplify cancer trials and accelerate post-pandemic recoveryhttps://pharmaphorum.com/views-and-analysis/collaborate-to-simplify-cancer-trials-and-accelerate-post-pandemic-recovery/
Cancer research faces uncertain post-COVID landscapeThere’s a bright future ahead for cancer research in the UK, but only if the government is able Share XCancer research faces uncertain post-COVID landscapehttps://deep-dive.pharmaphorum.com/magazine/oncology-2021/cancer-research-faces-uncertain-post-covid-landscape/
Surprise pandemic lessons for pharmaAsk people in most western nations to think back to 2019 and consider what they would have said Share XSurprise pandemic lessons for pharmahttps://deep-dive.pharmaphorum.com/magazine/oncology-2021/surprise-pandemic-lessons-for-pharma/
Lessons from the first generation of cell and gene oncology trialsAdvances in cell and gene science are paving the way for transformative cancer treatments, but there are still Share XLessons from the first generation of cell and gene oncology trialshttps://deep-dive.pharmaphorum.com/magazine/oncology-2021/lessons-from-the-first-generation-of-cell-gene-oncology-trials/
Oncology R&D: the patient insights we’re still missing, and how to catch upImagine you are a pharma executive working in oncology R&D. The landscape is rapidly becoming more competitive and Share XOncology R&D: the patient insights we’re still missing, and how to catch uphttps://deep-dive.pharmaphorum.com/magazine/oncology-2021/oncology-rd-patient-engagement/
Digital tools key to immuno-oncology’s future: reportIf ASCO 2021 proves anything, it’s that the explosion in immuno-oncology therapies over the last few years shows Share XDigital tools key to immuno-oncology’s future: reporthttps://deep-dive.pharmaphorum.com/magazine/oncology-2021/digital-tools-key-to-immuno-oncology-future-report/
Oncology and a year of COVID: lessons for the futureCOVID’s impact on cancer care and oncology research has been devastating, but the pandemic has also opened up Share XOncology and a year of COVID: lessons for the futurehttps://deep-dive.pharmaphorum.com/magazine/oncology-2021/oncology-and-a-year-of-covid-lessons-for-the-future/
